| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.2 |
| Gross profit | 0.0 | 0.1 |
| Profit before tax | -12.4 | -21.0 |
| Net income | -12.4 | -21.0 |
| EPS (diluted, $ a share) | $-0.08 | $-0.15 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: SLN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Silence Therapeutics plc: key numbers
- Share price
- $19.80Close, Nov 16
- Market cap
- $3.69B
- Shares outstanding
- 186.61MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Silence Therapeutics plc
All →Silence Therapeutics M&A Deal with Merck KGaA
Silence Therapeutics announced it has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany. The transaction is expected to close in the first quarter of 2027, subject to customary closing conditions and shareholder approval. While the filing also contains Q3 2026 financial results, the pending acquisition is the primary material event for investors.
- Counterparty
- Merck KGaA
Silence Therapeutics Signs $1.3B M&A Deal with Merck KGaA, Darmstadt, Germany
Silence Therapeutics has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany for approximately $1.3 billion in cash. Under the terms of the deal, Silence shareholders will receive $20.00 per ADS, representing a 130% premium to the company's recent closing price. The acquisition aims to strengthen Merck KGaA's specialty and rare disease pipeline, specifically incorporating Silence's Phase 2 siRNA candidate, Divesiran.
- Value
- $1.3B
- Counterparty
- Merck KGaA, Darmstadt, Germany
“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”
Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board
“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”
Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany